Literature DB >> 32497032

QuickStats: Prevalence of High Total Cholesterol* Among Adults Aged ≥20 Years, by Age Group and Sex - National Health and Nutrition Examination Survey, 2015-2018.

.   

Abstract

Entities:  

Year:  2020        PMID: 32497032      PMCID: PMC7315850          DOI: 10.15585/mmwr.mm6922a5

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


× No keyword cloud information.
During 2015–2018, the prevalence of high total cholesterol among adults aged ≥20 years was 11.4%, with no significant difference between men (10.5%) and women (12.1%). Prevalence was highest among adults aged 40–59 years (15.7%), followed by those aged ≥60 years (11.4%), and lowest among those aged 20–39 years (7.5%). Among men, the prevalence was highest among those aged 40–59 years (14.5%), followed by those aged 20–39 years (9.5%), and lowest among those aged ≥60 years (6.0%). Among women, the pattern was different, with women aged 20–39 years (5.5%) having a lower prevalence than either women aged 40–59 years (16.9%) or women aged ≥60 years (15.9%). Prevalence among women aged 20–39 years was lower than that among men in this age group, but prevalence was higher among women aged ≥60 years than it was among men of that age group. There was no significant difference between men and women for adults aged 40–59 years.
  2 in total

1.  Quantitative Water Permeability Mapping of Blood-Brain-Barrier Dysfunction in Aging.

Authors:  Jeremy N Ford; Qihao Zhang; Elizabeth M Sweeney; Alexander E Merkler; Mony J de Leon; Ajay Gupta; Thanh D Nguyen; Jana Ivanidze
Journal:  Front Aging Neurosci       Date:  2022-04-08       Impact factor: 5.702

2.  Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.

Authors:  Glenn Phillips; Catarina Abreu; Amit Goyal; Yuebing Li; Albert Whangbo; Deborah Gelinas; Edward Brauer; Sankha Bhattacharya
Journal:  Front Neurol       Date:  2022-01-18       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.